Achieve Life Sciences Inc (ACHV) Stock Price, Quote & News

Company Profile

Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms. It has license and supply agreements with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothel...

Industry: Biotechnology

Sector: Healthcare

Phone: 604 210 2217

Website: www.achievelifesciences.com

Address:

22722 29th Dr. SE, Suite 100, Bothell, United States

jacksparo May. 15 at 6:05 PM

$SLS $IBRX $CADL $ACHV $NRXP I am taking fantastic notes for my incoming plans and trades! Such a relaxing great day 😁😁!

2 · Reply

JackFlaps May. 15 at 3:33 PM

$ACHV market cap seems high for where the company is at currently. Obviously potential but $ 600 mil seems rich

1 · Reply

MasterChiefCov May. 13 at 9:47 PM

$ACHV How do you guys think this will react on the formal CRL issuing by the FDA? Do we think algos will dump or perhaps a bullish effect when no clinal deficiencies are present.

2 · Reply

Scubafrank May. 13 at 7:33 PM

$ACHV this gets near 5.00 by EOW

1 · Reply

Jakeipedia May. 13 at 2:22 PM

$ACHV 8000 shares let’s go

2 · Reply

ZacksSCR May. 13 at 1:53 PM

$ACHV CEO Enlists New Commercialization Team https://scr.zacks.com/news/news-details/2026/ACHV-CEO-Enlists-New-Commercialization-Team-article/default.aspx

0 · Reply

ChristIsKingg May. 13 at 10:05 AM

$ACHV Guys… I think this is it. I can see the finish line. We now have a competent leader, a new seasoned management team on board, and enough cash to last until commercialization. The new manufacturer, Adare, is strong and legitimate, and the Scooby-Doo Omnicom setup has been replaced by an in-house sales team. What more could you ask for? In 1.5 years, this will be at least $15.

1 · Reply

bobtheknob May. 12 at 10:32 PM

$ACHV Verona pharma timeline from FDA approval to buyout and what we could expect with Achieve. They also tapped non-dilutive financing after approval.

0 · Reply

bobtheknob May. 12 at 10:01 PM

$ACHV “three senior leadership appointments. Christopher Martin has joined the Company’s Board of Directors. Mark Zappia has joined as Senior Vice President, Commercial, where he will spearhead the Company’s commercial function. Jim Willis has joined as Vice President of Sales and Sales Enablement” all worked for Verona Pharma and instrumental in their buyout to Merck. Interesting it was a COPD drug and smoking cessation go hand in hand.

1 · Reply

bobtheknob May. 12 at 8:42 PM

$ACHV What a beautiful long term chart. We are sitting around long term resistance At $6. Probably soon to become support.

0 · Reply

Achieve Life Sciences files prospectus for resale of shares by holders

May 12, 2026, 8:30 AM EDT - 3 days ago

Achieve Life Sciences Earnings Call Transcript: Q1 2026

2026-05-12T11:58:27.000Z - 3 days ago

Achieve Life Sciences reports Q1 EPS (19c), consensus (30c)

2026-05-12T11:05:20.000Z - 3 days ago

Options Volatility and Implied Earnings Moves Today, May 12, 2026

GRWG HUYA HYLN LAR LCTX OGI ONON

May 12, 2026, 7:05 AM EDT - 3 days ago

Achieve Life Sciences Strengthens Board and Commercial Leadership with Three Senior Appointments from Team Previously at Verona Pharma

May 12, 2026, 7:00 AM EDT - 3 days ago

Achieve Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Updates

May 5, 2026, 8:30 AM EDT - 10 days ago

Achieve Life Sciences to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 12, 2026

2026-04-21T09:20:14.000Z - 24 days ago

Achieve Life Sciences initiated with a Buy at Canaccord

2026-04-20T20:46:40.000Z - 25 days ago

Achieve Life Sciences initiated with a Buy at Canaccord

2026-04-16T15:25:18.000Z - 4 weeks ago

Achieve Life Sciences announces $354M private placement

2026-04-16T14:03:48.000Z - 4 weeks ago

Achieve Life Sciences appoints Goldberg as CEO, names two leaders to board

Apr 16, 2026, 8:57 AM EDT - 4 weeks ago

Achieve Life Sciences Announces Appointment of Andrew D. Goldberg, MD, as Chief Executive Officer and to the Board of Directors

Apr 16, 2026, 8:53 AM EDT - 4 weeks ago

Achieve Life Sciences Announces Up to $354 Million Private Placement

Apr 15, 2026, 8:00 AM EDT - 4 weeks ago

Achieve Life Sciences Announces Operational Progress Including Completion of Technology Transfer to Adare Pharma Solutions

Mar 26, 2026, 8:30 AM EDT - 7 weeks ago

Achieve Life Sciences Announces Publication in Nicotine & Tobacco Research Linking Cytisinicline's Receptor Selectivity to Low Nausea Rates and Favorable Tolerability

Mar 24, 2026, 2:23 PM EDT - 7 weeks ago

Achieve Life Sciences Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Mar 24, 2026, 8:30 AM EDT - 7 weeks ago

Achieve Life Sciences Earnings Call Transcript: Q4 2025

2026-03-24T12:05:19.000Z - 7 weeks ago

Options Volatility and Implied Earnings Moves Today, March 24, 2026

ABSI AIR BRZE DPRO EVTL GME KBH

2026-03-24T11:10:44.000Z - 7 weeks ago

Achieve Life Sciences reports Q4 EPS (28c), consensus (28c)

Mar 24, 2026, 7:00 AM EDT - 7 weeks ago

Achieve Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

Mar 17, 2026, 8:30 AM EDT - 2 months ago

Achieve Life Sciences to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call and Webcast on March 24, 2026

2026-03-09T20:45:55.000Z - 2 months ago

Aeon Biopharma appoints John Bencich as CFO

AEON

2026-03-04T13:21:27.000Z - 2 months ago

Achieve Life Sciences announces new data on cytisinicline to be presented

Mar 4, 2026, 8:00 AM EST - 2 months ago

Achieve Life Sciences Presents Data at SRNT Demonstrating Successful Cessation in Smokers with Extensive Prior Treatment Exposure; and on Participant Experience in the ORCA-OL Study

2026-02-06T16:15:23.000Z - 3 months ago

H.C. Wainwright says Chantix news ‘significant win’ for Achieve Life Sciences

PFE

Jan 30, 2026, 4:05 PM EST - 3 months ago

Achieve Life Sciences Announced Granting of New Hire Inducement Awards

2026-01-23T21:10:26.000Z - 4 months ago

Achieve Life Sciences files $300M mixed securities shelf

2026-01-12T13:55:17.000Z - 4 months ago

Achieve Life Sciences confirms promotion of Mark Rubinstein to CMO

Jan 12, 2026, 8:47 AM EST - 4 months ago

Achieve Life Sciences Confirms Promotion of Dr. Mark Rubinstein to Chief Medical Officer

2026-01-05T16:45:30.000Z - 4 months ago

H.C. Wainwright names two best 2026 ideas in SMID-cap biopharma

CNTB

2025-12-30T16:10:10.000Z - 4 months ago

Achieve Life near FDA approval of smoking addiction treatment, Hunterbrook says

Dec 17, 2025, 4:11 PM EST - 5 months ago

Achieve Life Sciences to Host Meetings During the J.P. Morgan Healthcare Conference Week

2025-11-25T09:45:19.000Z - 6 months ago

Achieve Life Sciences initiated with an Outperform at Citizens JMP

Nov 6, 2025, 8:30 AM EST - 6 months ago

Achieve Life Sciences Earnings Call Transcript: Q3 2025

2025-11-06T12:05:50.000Z - 6 months ago

Achieve Life Sciences reports Q3 EPS (28c), consensus (26c)

Nov 6, 2025, 7:00 AM EST - 6 months ago

Achieve Life Sciences Reports Third Quarter 2025 Financial Results; Provides Updates on Cytisinicline Program

Nov 3, 2025, 8:30 AM EST - 6 months ago

Achieve Life Sciences Meets Key Milestones Advancing Cytisinicline NDA for Smoking Cessation

Oct 29, 2025, 8:30 AM EDT - 7 months ago

Achieve Life Sciences to Announce Third Quarter Financial Results and Host Conference Call and Webcast on November 6, 2025

Oct 20, 2025, 8:30 AM EDT - 7 months ago

Achieve Life Sciences Appoints Erik Atkisson as Chief Legal Officer

Oct 17, 2025, 7:30 AM EDT - 7 months ago

Achieve Life Sciences Receives FDA Commissioner's National Priority Voucher for Cytisinicline for Treatment of Nicotine Dependence for E-cigarette or Vaping Cessation

Oct 2, 2025, 4:01 PM EDT - 8 months ago

Achieve Life Sciences Announces Granting of New Hire Inducement Awards

Sep 22, 2025, 8:30 AM EDT - 8 months ago

Achieve Life Sciences Announces Publication in Thorax of Data Demonstrating Cytisinicline's Potential Efficacy and Tolerability for Smoking Cessation in Individuals with COPD

Sep 18, 2025, 8:30 AM EDT - 8 months ago

Achieve Life Sciences Promotes Craig Donnelly to Chief Operations Officer

Sep 11, 2025, 5:01 PM EDT - 8 months ago

Achieve Life Sciences Names Dr. Mark Rubinstein Interim Chief Medical Officer

Sep 8, 2025, 11:00 AM EDT - 8 months ago

Achieve Life Sciences Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 8:30 AM EDT - 9 months ago

Achieve Life Sciences Announces FDA Acceptance of Cytisinicline New Drug Application for Treatment of Nicotine Dependence for Smoking Cessation

Sep 2, 2025, 8:30 AM EDT - 9 months ago

Achieve Life Sciences Announces Participation at Upcoming Investor Conferences

Aug 7, 2025, 8:30 AM EDT - 10 months ago

Achieve Life Sciences Earnings Call Transcript: Q2 2025

Aug 7, 2025, 7:30 AM EDT - 10 months ago

Achieve Life Sciences Reports Second Quarter 2025 Financial Results; Provides Updates on Cytisinicline Program

Jul 29, 2025, 8:30 AM EDT - 10 months ago

Achieve Life Sciences to Participate in the BTIG Virtual Biotechnology Conference

Jul 24, 2025, 8:30 AM EDT - 10 months ago

Achieve Life Sciences to Announce Second Quarter Financial Results and Host Conference Call and Webcast on August 7, 2025

Jun 30, 2025, 7:52 PM EDT - 11 months ago

Achieve Life Sciences Announces Closing of Public Offering of Common Stock and Partial Exercise of Underwriters' Option to Purchase Additional Securities

Jun 26, 2025, 11:43 PM EDT - 11 months ago

Achieve Life Sciences Announces Pricing of $45.0 Million Underwritten Public Offering

Jun 26, 2025, 4:03 PM EDT - 11 months ago

Achieve Life Sciences Announces Proposed Underwritten Public Offering

Jun 26, 2025, 4:02 PM EDT - 11 months ago

Achieve Life Sciences Announces Partnership with Omnicom to Execute Integrated, Data-Driven Launch of the First Potential New Treatment for Nicotine Dependence in Nearly Two Decades

OMC

Jun 4, 2025, 5:30 PM EDT - 1 year ago

Achieve Life Sciences Transcript: Jefferies Global Healthcare Conference 2025

May 28, 2025, 8:30 AM EDT - 1 year ago

Achieve Life Sciences to Present at the Jefferies Global Healthcare Conference

May 20, 2025, 8:30 AM EDT - 1 year ago

Achieve Life Sciences to Present New Data at the 2025 ATS International Conference Demonstrating that Cytisinicline Reduced Cravings and Nicotine Intake

May 13, 2025, 8:30 AM EDT - 1 year ago

Achieve Life Sciences Earnings Call Transcript: Q1 2025

May 13, 2025, 7:30 AM EDT - 1 year ago

Achieve Life Sciences Reports First Quarter 2025 Financial Results and Highlights Updates in Cytisinicline Program

May 6, 2025, 8:30 AM EDT - 1 year ago

Achieve Life Sciences to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 13, 2025

Apr 21, 2025, 11:19 AM EDT - 1 year ago

Achieve Life Sciences Announces Cytisinicline Phase 3 ORCA-3 Trial Publication on Smoking Cessation in JAMA Internal Medicine

Mar 12, 2025, 11:30 AM EDT - 1 year ago

Achieve Life Sciences Transcript: Barclays 27th Annual Global Healthcare Conference 2025

Mar 11, 2025, 8:30 AM EDT - 1 year ago

Achieve Life Sciences Earnings Call Transcript: Q4 2024

Mar 11, 2025, 7:30 AM EDT - 1 year ago

Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2024 and Provides Update on the Cytisinicline Development Program

Mar 7, 2025, 8:30 AM EST - 1 year ago

Achieve Life Sciences to Present at the Barclays 27th Annual Global Healthcare Conference

Mar 6, 2025, 8:30 AM EST - 1 year ago

Achieve Life Sciences to Announce Fourth Quarter and Year-End 2024 Financial Results and Host Conference Call and Webcast on March 11, 2025

Feb 11, 2025, 10:00 AM EST - 1 year ago

Achieve Life Sciences Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Feb 11, 2025, 8:30 AM EST - 1 year ago

Achieve Life Sciences to Present at the Oppenheimer Healthcare Life Sciences Conference

Feb 10, 2025, 8:30 AM EST - 1 year ago

Achieve Life Sciences Announces Positive Outcome of Second Data Safety Monitoring Committee Review for the ORCA-OL Clinical Trial

Jan 10, 2025, 8:30 AM EST - 1 year ago

Achieve Life Sciences Appoints Dr. Kristen Slaoui and Nancy Phelan to its Board of Directors

Jan 7, 2025, 8:30 AM EST - 1 year ago

Achieve Life Sciences Announces Critical Milestone Successfully Reached in ORCA-OL Cytisinicline Clinical Trial Required for NDA Submission

Dec 9, 2024, 8:30 AM EST - 1 year ago

Achieve Life Sciences Appoints Mark Oki as Chief Financial Officer

Dec 3, 2024, 8:30 AM EST - 1 year ago

Achieve Life Sciences to Advance First Vaping Cessation Therapy After Successful End-of-Phase 2 Meeting with FDA

Nov 25, 2024, 7:54 AM EST - 1 year ago

Smoking Cessation Pipeline Insight 2024, with Focus on Emerging Drugs Cytisinicline (Achieve Life Sciences), EMB-001(Embera Pharmaceuticals) and SBP-9330 (Camino Pharma)

Nov 7, 2024, 4:30 PM EST - 1 year ago

Achieve Life Sciences Earnings Call Transcript: Q3 2024

Oct 23, 2024, 8:00 AM EDT - 1 year ago

Achieve Life Sciences President and CMO, Dr. Cindy Jacobs, Speaks at FDA and NIH Smoking Cessation Public Meeting

Oct 16, 2024, 8:00 AM EDT - 1 year ago

Achieve Life Sciences Promotes Jaime Xinos to Chief Commercial Officer to Advance Commercial Readiness of Cytisinicline

Oct 1, 2024, 8:45 AM EDT - 1 year ago

Achieve Life Sciences Strengthens Leadership with Appointment of Dr. Mark Rubinstein, Nicotine Dependence Expert, as New Head of Medical Affairs

jacksparo May. 15 at 6:05 PM

$SLS $IBRX $CADL $ACHV $NRXP I am taking fantastic notes for my incoming plans and trades! Such a relaxing great day 😁😁!

2 · Reply

JackFlaps May. 15 at 3:33 PM

$ACHV market cap seems high for where the company is at currently. Obviously potential but $ 600 mil seems rich

1 · Reply

MasterChiefCov May. 13 at 9:47 PM

$ACHV How do you guys think this will react on the formal CRL issuing by the FDA? Do we think algos will dump or perhaps a bullish effect when no clinal deficiencies are present.

2 · Reply

Scubafrank May. 13 at 7:33 PM

$ACHV this gets near 5.00 by EOW

1 · Reply

Jakeipedia May. 13 at 2:22 PM

$ACHV 8000 shares let’s go

2 · Reply

ZacksSCR May. 13 at 1:53 PM

$ACHV CEO Enlists New Commercialization Team https://scr.zacks.com/news/news-details/2026/ACHV-CEO-Enlists-New-Commercialization-Team-article/default.aspx

0 · Reply

ChristIsKingg May. 13 at 10:05 AM

1 · Reply

bobtheknob May. 12 at 10:32 PM

$ACHV Verona pharma timeline from FDA approval to buyout and what we could expect with Achieve. They also tapped non-dilutive financing after approval.

0 · Reply

bobtheknob May. 12 at 10:01 PM

1 · Reply

bobtheknob May. 12 at 8:42 PM

$ACHV What a beautiful long term chart. We are sitting around long term resistance At $6. Probably soon to become support.

0 · Reply

BuyHighSellLow66 May. 12 at 8:33 PM

$ACHV and BULL gonna make me a millionaire. 🤙

0 · Reply

Mugshot May. 12 at 8:05 PM

$ACHV great strong close

1 · Reply

zmanx May. 12 at 5:58 PM

$ACHV new 52wk high hit today!

0 · Reply

SaySomethingNice May. 12 at 4:07 PM

$ACHV looking forward ahead for sure.

0 · Reply

Sieppo May. 12 at 4:05 PM

$ACHV Webull has updated the market cap today.

1 · Reply

SaySomethingNice May. 12 at 4:04 PM

$ACHV

0 · Reply

SaySomethingNice May. 12 at 4:02 PM

$ACHV this is a $15-$25 stock ahead AT LEAST.

0 · Reply

Greyhound_ May. 12 at 3:51 PM

$ACHV Expect some profit taking, the stock has doubled in just a few months off recent lows. Here is what I see from my perch: 1. For the first time, a truly capable management team who has the expertise to get FDA approval. 2. A healthy balance sheet with plenty of cash to go at it alone. 3. A national crisis = tremendous market opportunities with correct marketing + gov't backing with pricing reimbursement 4. US-based supply chain (another first) The downside: a lot more shares than necessary have been issued. The upside is still bright in my opinion. We'll see.

0 · Reply

bobtheknob May. 12 at 2:34 PM

$ACHV They would not answer the question if the expected CRL is class 1 or class 2. There is theoretically a chance for class 1 with a 2 month review. We will just have to wait for the FDA update.

1 · Reply

Sieppo May. 12 at 2:28 PM

$ACHV listening to the cc, the new CEO sounds very good and convincing!

0 · Reply

bobtheknob May. 12 at 2:13 PM

$ACHV Investors have much more confidence in the new management team!

0 · Reply

MarketBeat May. 12 at 2:09 PM

https://marketbeat.com/a/8650586/ $ACHV Achieve Life Sciences Q1 Earnings Call Highlights

0 · Reply

Market Cap	317.28M
Revenue (ttm)	0.00
Net Income (ttm)	-54.65M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.25

Volume	1,294,600
Avg Vol	1,286,836
Day's Range	N/A - N/A
Shares Out	53.23M
Stochastic %K	80%
Beta	2.25
Analysts	Strong Sell
Price Target	$14.62